Patient capital is in short supply
Investors demand returns — and many want them to materialize overnight. But not every investment opportunity has that kind of potential. Some take years to pay off, but yield big results when they do.
Mutual fund managers often choose not to add stocks like this to their portfolios, even when they know they exist. This is because fund managers are incentivized to plan for the short term by the structure of their compensation packages and the day-to-day obligations of managing a mutual fund.
But research from the University of Notre Dame’s Rafael Zambrana argues that mutual fund fee structures can be set up to incentivize long-term thinking, and this yields better results for investors with the patience to commit their capital.
“In the 1960s, investors held stocks for an average of eight years. Today, the average is just six months,” says Zambrana, an assistant professor of finance at the Mendoza College of Business.
“And that number includes securities held by institutional investors like mutual funds. When institutional investors like hedge funds participate in high-frequency trading, they promote a short-term investment horizon. And that seems to be what investors are demanding in the asset management industry. Patient capital is in short supply.”
Fund managers’ compensation is often based on their performance relative to a benchmark and usually measured over a short period of time. This can be one year or even less, and fund managers are incentivized to think on that timeline. Concerns about the evaluation of their own performance can impact their decisions. They may choose not to purchase some stocks because they won’t perform well in the short term.
Fund managers also need to consider investor behavior. The underlying investors in mutual funds can withdraw their money at any time, and fund managers need to provide it to them when they do. That means managers might need to sell stocks to pay investors, and this makes profitable illiquid stocks less attractive. A more liquid stock can easily be bought and sold with minimal effect to its price. If a fund manager needs to sell them quickly, it won’t drive the stock’s price down too much.
In “Capital Commitment and Performance: The Role of Mutual Fund Charges,” forthcoming in the Journal of Financial and Quantitative Analysis, Zambrana proposes a model that analyzes the performance of mutual funds with different sales fee structures. The research found that fee structures that incentivizes the underlying investors to be more patient with their investments allows fund managers to better take advantage of long-term opportunities, and especially stocks with lower levels of liquidity. This ultimately makes investors more money.
“The main challenge for portfolio managers is a mismatch with the investment horizon of value investing,” says Zambrana.
“Even if they believe a stock is undervalued and will appreciate, they may not want to add it to their portfolio because of the short-term obligations of managing a fund. We argue that the willingness to invest for the long term should be rewarded. We call that committed capital, and it provides insurance to portfolio managers, so you should reward it.”
When retail investors buy shares in a mutual fund, they are putting their trust in a fund manager who manages the fund’s assets with the goal of beating the market. To obtain this service, the underlying investors pay a fee. These fees are typically charged annually, but by front-loading the fees, mutual funds can attract more long-term investors.
When a higher fee is charged at the time of investment, and a discount offered on annual fees, there is less incentive for people to withdraw their money, because they have already paid a larger amount of their fees. This helps prevent outflows of money caused by underlying investors cashing in. It also allows the fund managers to lock more capital into good long-term investments, such as companies that are R&D intensive or invest in tangible assets like real estate. Shares in these companies are sometimes likely to appreciate over the long term, but are difficult to sell quickly.
In Zambrana’s model, funds with sizable front-loaded fees outperformed funds with higher annual fees.
“Patient capital is the source of outperformance. Mutual funds that have more of it can take on more risk. It allows portfolio managers to invest in stocks that are less liquid,” says Zambrana.
“It is not really a concern if they will have a harder time selling, because they won't need to sell in the short term. That leads to better returns. Fund managers can invest with a longer duration, and wait until the investment capitalizes. The underlying mechanism is that patient capital allows portfolio managers to take advantage of their skills to beat the market.”
Rafael Zambrana is an assistant professor of finance at the University of Notre Dame Mendoza College of Business. His research deals primarily with the investment behavior of institutional investors and the impact of their trades on stock markets.
Latest Faculty & Staff
- Opioid epidemic reaches beyond health impacts to influence politicsVicky Barone, assistant professor of economics at Notre Dame, researched the origins and development of the opioid epidemic and found that the unregulated marketing of potent painkillers led to increased access to prescription opioids and subsequent overdose mortalities. Tracing the long-term consequences of opioid overdose deaths on the political landscape in America, she found an increased support for conservative beliefs and Republican candidates.
- Doug Thompson appointed inaugural executive director of diversity and engagementDoug Thompson, current vice president for equity and inclusion at Gustavus Adolphus College, has been appointed as the inaugural executive director of diversity and engagement in the University of Notre Dame’s Division of Student Affairs, effective July 1.
- There’s no ‘one size fits all’ when it comes to addressing men’s health issues globallyAt a time when health resources are at a premium and need to be wisely allocated, health professionals must find points within men’s lives when it makes the most sense to intervene and advocate for preventive care for promoting better health outcomes. Life transitions such as marriage and fatherhood are often pivotal and crucial intervention points. But just like every man is different, health concerns across global communities differ as well. Research from the University of Notre Dame finds that not all life transitions produce the same health results, and not all men’s global health policies should look the same from one country to another.
- Three Notre Dame faculty named 2024 Guggenheim FellowsBarbara Montero, a professor of philosophy; Gretchen Reydams-Schils, a professor in the Program of Liberal Studies; and Roy Scranton, an associate professor of English and director of the Creative Writing Program and the Environmental Humanities Initiative, are among the 188 scholars, scientists and artists chosen from approximately 3,000 applicants for the fellowship. The Guggenheim Foundation awards these fellowships to outstanding scholars in order to add to the educational, literary, artistic and scientific power of the country.
- Essays on democracy draw attention to critical threats, explore safeguards ahead of Jan. 6Shortly after Jan. 6, 2021, when a mob stormed the U.S. Capitol building, Notre Dame’s Rooney Center for the Study of American Democracy established the January 6th, 2025, Project, which includes 10 Notre Dame faculty who are preeminent scholars of democracy. In an effort to understand the social, political, psychological and demographic factors that led to that troublesome day, the group created a collection of 14 essays aimed at drawing attention to the vulnerabilities in our democratic system and the threats building against it, hoping to create consensus on ways to remedy both problems.
- Carter Snead testifies before US Senate Judiciary CommitteeO. Carter Snead, the Charles E. Rice Professor of Law and director of the de Nicola Center for Ethics and Culture at the University of Notre Dame, offered expert testimony on Wednesday (March 20) before the U.S. Senate Committee on the Judiciary on the current legal landscape following the landmark Supreme Court decision in Dobbs v. Jackson Women’s Health Organization.